LONDON - The European Commission has approved AstraZeneca (NASDAQ:AZN)'s Voydeya (danicopan) as an add-on treatment for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who suffer from residual haemolytic anaemia despite being treated with ravulizumab or eculizumab.
This decision follows the ALPHA Phase III trial's positive outcomes, which demonstrated that Voydeya, an oral Factor D inhibitor, improved haemoglobin levels and reduced symptoms of anaemia and fatigue.
PNH is a rare and life-threatening blood disorder characterized by the destruction of red blood cells and potential blood clots. The ALPHA trial showed the efficacy of Voydeya as an add-on to standard C5 inhibitor therapies, addressing the needs of PNH patients who experience clinically significant extravascular haemolysis (EVH).
Professor Hubert Schrezenmeier, MD, from The University of Ulm, highlighted the significance of this approval for patients with PNH who continue to show symptoms of anaemia due to EVH. He noted that Voydeya offers an option to manage EVH manifestations while maintaining disease control with current C5 inhibitor therapies.
Marc Dunoyer, CEO of Alexion (NASDAQ:ALXN), a subsidiary of AstraZeneca, expressed the company's commitment to making Voydeya available to patients across Europe and to expanding access globally. The trial's results, indicating that Voydeya met the primary endpoint of change in haemoglobin levels and key secondary endpoints, were well received, with the drug being generally well tolerated.
Voydeya has previously received Breakthrough Therapy designation from the FDA and PRIME status from the EMA. It has also been approved in the US and Japan for the treatment of PNH, with ongoing regulatory reviews in additional countries.
The approval of Voydeya in the EU is a step forward for AstraZeneca and its efforts to provide treatments for rare diseases.
AstraZeneca, headquartered in Cambridge, UK, is known for its focus on the discovery and commercialization of prescription medicines across various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals.
This news report is based on a press release statement from AstraZeneca.
InvestingPro Insights
As AstraZeneca (NASDAQ: AZN) secures another approval for its treatment Voydeya, the company's financial health and market performance continue to be of interest to investors. With a market capitalization of $216.37 billion, AstraZeneca stands as a prominent player in the Pharmaceuticals industry. The company's commitment to innovation in rare diseases like PNH is reflected in its financial metrics, including a gross profit margin of 82.45% in the last twelve months as of Q4 2023, indicating a strong ability to generate revenue over its cost of goods sold.
Investors may also note that AstraZeneca's P/E ratio stands at 27.52, adjusted for the last twelve months as of Q4 2023. This metric, combined with a PEG ratio of just 0.45, suggests that the company's earnings growth is expected to be robust relative to its current earnings multiple. Such financial indicators are particularly relevant as the firm expands the availability of its treatments like Voydeya.
Two InvestingPro Tips that may be of interest to investors considering AstraZeneca's stock are:
- The company is trading at a high Price / Book multiple of 5.5, which might indicate investor confidence in the company's assets and future growth prospects.
- Net income is expected to grow this year, a positive signal for potential investors looking for companies with a strong earnings outlook.
For those looking for more in-depth analysis and additional InvestingPro Tips, there are 12 more tips available for AstraZeneca on InvestingPro. Plus, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain further insights into AstraZeneca's financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.